

# Bruce C Carleton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4543046/publications.pdf>

Version: 2024-02-01

220  
papers

6,905  
citations

81743

39  
h-index

76769

74  
g-index

232  
all docs

232  
docs citations

232  
times ranked

8114  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. <i>Journal of Clinical Oncology</i> , 2012, 30, 1422-1428.	0.8	341
2	More Codeine Fatalities After Tonsillectomy in North American Children. <i>Pediatrics</i> , 2012, 129, e1343-e1347.	1.0	334
3	Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. <i>Nature Genetics</i> , 2009, 41, 1345-1349.	9.4	287
4	Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Caseâ€“Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 31-35.	2.3	284
5	A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. <i>Nature Genetics</i> , 2015, 47, 1079-1084.	9.4	214
6	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	2.3	211
7	Recommendations for genetic testing to reduce the incidence of anthracyclineâ€“induced cardiotoxicity. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 683-695.	1.1	188
8	Recommendations for <sc>HLA</sc>â€“B*15:02 and <sc>HLA</sc>â€“A*31:01 genetic testing to reduce the risk of carbamazepineâ€“induced hypersensitivity reactions. <i>Epilepsia</i> , 2014, 55, 496-506.	2.6	173
9	Validation of variants in <i>SLC28A3</i> and <i>UGT1A6</i> as genetic markers predictive of anthracyclineâ€“induced cardiotoxicity in children. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1375-1381.	0.8	166
10	Differential effect of the rs4149056 variant in SLC01B1 on myopathy associated with simvastatin and atorvastatin. <i>Pharmacogenomics Journal</i> , 2012, 12, 233-237.	0.9	158
11	Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 153-163.	0.7	155
12	Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011, 118, 624-628.	1.1	151
13	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
14	Direct Health Care Costs Associated with Asthma in British Columbia. <i>Canadian Respiratory Journal</i> , 2010, 17, 74-80.	0.8	122
15	HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 142-149.	2.3	110
16	Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 243-251.	2.3	109
17	Central Nervous System Depression of Neonates Breastfed by Mothers Receiving Oxycodone for Postpartum Analgesia. <i>Journal of Pediatrics</i> , 2012, 160, 33-37.e2.	0.9	108
18	Genetic variants in <i>SLC22A17</i> and <i>SLC22A7</i> are associated with anthracycline-induced cardiotoxicity in children. <i>Pharmacogenomics</i> , 2015, 16, 1065-1076.	0.6	95

#	ARTICLE	IF	CITATIONS
19	Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. <i>Lancet Oncology</i> , 2019, 20, e29-e41.	5.1	90
20	Effect of a clinical pathway on the hospitalisation rates of children with asthma: a prospective study. <i>Archives of Disease in Childhood</i> , 2007, 92, 60-66.	1.0	84
21	Fatal Hydrocodone Overdose in a Child: Pharmacogenetics and Drug Interactions. <i>Pediatrics</i> , 2010, 126, e986-e989.	1.0	84
22	Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 713-721.	0.9	70
23	Prediction of Codeine Toxicity in Infants and Their Mothers Using a Novel Combination of Maternal Genetic Markers. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 692-699.	2.3	69
24	The emerging era of pharmacogenomics: current successes, future potential, and challenges. <i>Clinical Genetics</i> , 2014, 86, 21-28.	1.0	68
25	The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology. <i>Thyroid</i> , 2010, 20, 681-687.	2.4	67
26	Does Ibuprofen Worsen COVID-19?. <i>Drug Safety</i> , 2020, 43, 611-614.	1.4	66
27	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 428-436.	1.0	64
28	Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. <i>BMJ: British Medical Journal</i> , 2004, 328, 560.	2.4	58
29	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 402-410.	2.3	56
30	Association of Repeated Intravitreal Bevacizumab Injections With Risk for Glaucoma Surgery. <i>JAMA Ophthalmology</i> , 2017, 135, 363.	1.4	53
31	Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment. <i>Vaccine</i> , 2018, 36, 6202-6211.	1.7	53
32	Pharmacogenetic Testing: Time for Clinical Practice Guidelines. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 924-927.	2.3	52
33	Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: A retrospective cohort study. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 576-577.	0.8	48
34	The Added Burden of Comorbidity in Patients with Asthma. <i>Journal of Asthma</i> , 2009, 46, 1021-1026.	0.9	48
35	Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 423-431.	1.0	47
36	Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 102-104.	0.7	46

#	ARTICLE	IF	CITATIONS
37	Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. <i>Circulation</i> , 2022, 145, 279-294.	1.6	46
38	CYP2D6 Polymorphisms and Codeine Analgesia in Postpartum Pain Management: A Pilot Study. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 425-432.	1.0	45
39	Genetic variation in <i>CFH</i> predicts phenytoin-induced maculopapular exanthema in European-descent patients. <i>Neurology</i> , 2018, 90, e332-e341.	1.5	43
40	Prescription drug dispensing profiles for one million children: a population-based analysis. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 581-588.	0.8	41
41	Codeine-related deaths: The role of pharmacogenetics and drug interactions. <i>Forensic Science International</i> , 2014, 239, 50-56.	1.3	41
42	Association Between <i>SLC16A5</i> Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. <i>JAMA Oncology</i> , 2017, 3, 1558.	3.4	41
43	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.0	41
44	Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 274-283.	2.7	41
45	<i>VKORC1</i> and <i>CYP2C9</i> genotypes are predictors of warfarin-related outcomes in children. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1055-1062.	0.8	36
46	RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. <i>Cell Stem Cell</i> , 2021, 28, 2076-2089.e7.	5.2	36
47	Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2018, 9, 1111.	1.6	35
48	A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. <i>PLoS ONE</i> , 2013, 8, e70073.	1.1	34
49	Identifying Persons with Treated Asthma Using Administrative Data via Latent Class Modelling. <i>Health Services Research</i> , 2008, 43, 733-754.	1.0	33
50	Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. <i>Paediatric Drugs</i> , 2016, 18, 251-260.	1.3	33
51	Association of Postoperative Topical Prostaglandin Analog or Beta-Blocker Use and Incidence of Pseudophakic Cystoid Macular Edema. <i>Journal of Glaucoma</i> , 2018, 27, 402-406.	0.8	32
52	Further Investigation of the Role of <i>ACYP2</i> and <i>WFS1</i> Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 1866-1871.	3.2	32
53	Common variation near <i>IRF6</i> is associated with IFN- $\gamma$ -induced liver injury in multiple sclerosis. <i>Nature Genetics</i> , 2018, 50, 1081-1085.	9.4	32
54	The influence of genetic variation on late toxicities in childhood cancer survivors: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 154-167.	2.0	31

#	ARTICLE	IF	CITATIONS
55	Statin use and the risk of Parkinson disease: a nested case control study. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 1272-1273.	0.8	30
56	Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. <i>Pharmacogenomics</i> , 2017, 18, 931-943.	0.6	30
57	Apnea and Oxygen Desaturations in Children Treated with Opioids after Adenotonsillectomy for Obstructive Sleep Apnea Syndrome. <i>Paediatric Drugs</i> , 2012, 14, 411-415.	1.3	29
58	Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. <i>Pharmacogenomics Journal</i> , 2014, 14, 160-170.	0.9	29
59	Genotypic Approaches to Therapy in Children: A National Active Surveillance Network (GATC) to Study the Pharmacogenomics of Severe Adverse Drug Reactions in Children. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 177-192.	1.8	28
60	Physician Variability in Treating Pain and Irritability of Unknown Origin in Children with Severe Neurological Impairment. <i>Pain Research and Management</i> , 2013, 18, 243-248.	0.7	28
61	Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1444-1450.	1.2	28
62	Pharmacogenomics and its implications for autoimmune disease. <i>Journal of Autoimmunity</i> , 2007, 28, 122-128.	3.0	27
63	Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer. <i>JAMA Network Open</i> , 2020, 3, e203639.	2.8	27
64	A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. <i>PLoS ONE</i> , 2019, 14, e0210646.	1.1	26
65	Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 65-84.	4.2	26
66	Quantifying Adverse Drug Events. <i>Drug Safety</i> , 2004, 27, 757-761.	1.4	25
67	Cocaine adulterant linked to neutropenia. <i>Cmaj</i> , 2010, 182, 57-59.	0.9	25
68	Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors. <i>Medicine (United States)</i> , 2010, 89, 107-113.	0.4	25
69	CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 521-532.	1.1	25
70	Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome. <i>Neurology</i> , 2017, 89, 792-795.	1.5	24
71	Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. <i>PM and R</i> , 2018, 10, 235-243.	0.9	24
72	Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 350-359.	2.3	24

#	ARTICLE	IF	CITATIONS
73	Application of principal component analysis to pharmacogenomic studies in Canada. <i>Pharmacogenomics Journal</i> , 2009, 9, 362-372.	0.9	23
74	Communicating Pharmacogenetic Research Results to Breastfeeding Mothers Taking Codeine: A Pilot Study of Perceptions and Benefits. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 792-795.	2.3	23
75	Morphine biotransformation genes and neonatal clinical factors predicted behaviour problems in very preterm children at 18 months. <i>EBioMedicine</i> , 2019, 40, 655-662.	2.7	23
76	Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 228-239.	0.8	22
77	Pharmacogenomics and adverse drug reactions in children. <i>Frontiers in Genetics</i> , 2014, 5, 78.	1.1	22
78	Oral morphine dosing predictions based on single dose in healthy children undergoing surgery. <i>Paediatric Anaesthesia</i> , 2017, 27, 28-36.	0.6	22
79	Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 28-39.	0.7	21
80	Association of Antidepressant Use With Drug-Related Extrapyrimal Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 349-356.	0.7	21
81	Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. <i>Genes</i> , 2019, 10, 364.	1.0	21
82	Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 253-253.	2.3	20
83	Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children. <i>Pediatric Research</i> , 2015, 78, 44-47.	1.1	20
84	Pharmacogenomics and active surveillance for serious adverse drug reactions in children. <i>Pharmacogenomics</i> , 2010, 11, 1269-1285.	0.6	19
85	Hearing loss in Mexican children treated with cisplatin. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2014, 78, 1456-1460.	0.4	19
86	Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2016, 163, 53-58.	1.7	19
87	Paediatric adverse drug reaction reporting: understanding and future directions. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2007, 14, e45-57.	1.9	19
88	Fifty years of pediatric asthma in developed countries: How reliable are the basic data sources?. <i>Pediatric Pulmonology</i> , 2012, 47, 211-219.	1.0	18
89	Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study. <i>Laryngoscope</i> , 2017, 127, 229-232.	1.1	18
90	The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. <i>Cancer</i> , 2022, 128, 169-179.	2.0	18

#	ARTICLE	IF	CITATIONS
91	Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2013, 20, e369-96.	1.4	18
92	Putative Association of ABCB1 2677G>T/A With Oxycodone-Induced Central Nervous System Depression in Breastfeeding Mothers. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 466-472.	1.0	17
93	Life-Threatening Adverse Events Following Therapeutic Opioid Administration in Adults: Is Pharmacogenetic Analysis Useful?. <i>Pain Research and Management</i> , 2013, 18, 133-136.	0.7	17
94	Hair cortisol as a hypothalamic-pituitary-adrenal axis biomarker in pregnant women with asthma: a retrospective observational study. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 176.	0.9	17
95	Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study. <i>PLoS ONE</i> , 2018, 13, e0204799.	1.1	17
96	Considerations for Implementing Precision Therapeutics for Children. <i>Clinical and Translational Science</i> , 2019, 12, 140-150.	1.5	17
97	Risk of Extrapyrmidal Adverse Events With Aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 472-474.	0.7	16
98	Vincristine-induced peripheral neurotoxicity: A prospective cohort. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 15-28.	0.3	16
99	Palivizumab for the prevention of respiratory syncytial virus infection. <i>Canadian Family Physician</i> , 2010, 56, 769-72.	0.1	16
100	Pharmacogenomic diversity in Singaporean populations and Europeans. <i>Pharmacogenomics Journal</i> , 2014, 14, 555-563.	0.9	15
101	Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811769033.	0.6	15
102	Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review. <i>CNS Drugs</i> , 2018, 32, 917-938.	2.7	15
103	Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review. <i>Drugs - Real World Outcomes</i> , 2020, 7, 97-107.	0.7	15
104	Drug formulary decision-making in two regional health authorities in British Columbia, Canada. <i>Health Policy</i> , 2008, 88, 308-316.	1.4	14
105	High use of health services in patients with suboptimal asthma drug regimens: a population-based assessment in British Columbia, Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 744-751.	0.9	14
106	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. <i>JAMA Oncology</i> , 2021, 7, 1550.	3.4	14
107	The Dimensionality and Gender Differential Item Functioning of the Mini Asthma Quality of Life Questionnaire (MiniAQLQ). <i>Social Indicators Research</i> , 2004, 68, 91-105.	1.4	13
108	Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1143-1145.	1.1	13

#	ARTICLE	IF	CITATIONS
109	Analyses of Adverse Drug Reactions—National Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 356-363.	1.0	13
110	Evidence-Based Pharmacotherapy: Review of Basic Concepts and Applications in Clinical Practice. <i>Annals of Pharmacotherapy</i> , 1998, 32, 1193-1200.	0.9	12
111	Active surveillance systems for pediatric adverse drug reactions: an idea whose time has come. <i>Current Therapeutic Research</i> , 2001, 62, 738-742.	0.5	12
112	Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 57-59.	0.9	12
113	Pathways to Overmedication and Polypharmacy. , 2015, , 125-148.		12
114	Association Between Regulatory Advisories and Codeine Prescribing to Postpartum Women. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1861.	3.8	12
115	A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1083-1090.	1.6	12
116	Genetic determinants of cocaine-associated agranulocytosis. <i>BMC Research Notes</i> , 2015, 8, 240.	0.6	12
117	Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines. <i>PLoS ONE</i> , 2017, 12, e0175711.	1.1	12
118	CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2020, 20, 306-319.	0.9	12
119	An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 723-734.	1.5	12
120	Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 679-699.	4.2	12
121	Apnea and Oxygen Desaturations in Children Treated with Opioids after Adenotonsillectomy for Obstructive Sleep Apnea Syndrome. <i>Paediatric Drugs</i> , 2012, 14, 411-415.	1.3	12
122	Pharmacogenomic testing in paediatrics: Clinical implementation strategies. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4297-4310.	1.1	12
123	Postpartum Maternal Codeine Therapy and the Risk of Adverse Neonatal Outcomes. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 378-380.	1.0	11
124	Use of pharmacogenomics in pediatric renal transplant recipients. <i>Frontiers in Genetics</i> , 2015, 6, 41.	1.1	11
125	Risperidone and Risk of Gynecomastia in Young Men. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 671-673.	0.7	11
126	Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1083-1086.	1.6	11



#	ARTICLE	IF	CITATIONS
127	Use of oseltamivir in children. <i>Canadian Family Physician</i> , 2009, 55, 1199-201.	0.1	11
128	Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2011, 18, e76-88.	1.4	11
129	Risk of Gynecomastia with Users of Proton Pump Inhibitors. <i>Pharmacotherapy</i> , 2019, 39, 614-618.	1.2	10
130	Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. <i>Pharmacogenomics Journal</i> , 2020, 20, 621-628.	0.9	10
131	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. <i>JMIR Research Protocols</i> , 2019, 8, e11868.	0.5	10
132	Demonstrating Utility of Pharmacogenetics in Pediatric Populations: Methodological Considerations. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 757-759.	2.3	9
133	Suspected Opioid Overdose Case Resolved by CYP2D6 Genotyping. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 121-123.	1.0	9
134	Medication Errors: Neonates, Infants and Children Are the Most Vulnerable!. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2008, 13, 65-67.	0.3	9
135	Paediatric oral formulations: Why don't our kids have the medicines they need?. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4337-4348.	1.1	9
136	Cancer Pharmacogenomics in Children: Research Initiatives and Progress to Date. <i>Paediatric Drugs</i> , 2013, 15, 71-81.	1.3	8
137	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1305-1317.	1.0	8
138	Development of a broad-based ADME panel for use in pharmacogenomic studies. <i>Pharmacogenomics</i> , 2014, 15, 1185-1195.	0.6	8
139	Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 684-686.	2.9	8
140	Assessment of hair cortisol as a potential biomarker for possible adrenal suppression due to inhaled corticosteroid use in children with asthma: A retrospective observational study. <i>Clinical Biochemistry</i> , 2018, 56, 26-32.	0.8	8
141	Reducing anthracycline-induced cardiotoxicity through pharmacogenetics. <i>Pharmacogenomics</i> , 2018, 19, 1147-1150.	0.6	8
142	Risk of Anterior Segment Complications Associated With the Live Herpes Zoster Vaccine: Evidence From a Health-Claim Database. <i>Cornea</i> , 2018, 37, 952-956.	0.9	8
143	Oral Fluoroquinolone Prescribing to Children in the United States From 2006 to 2015. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 268-270.	1.1	8
144	Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 95-99.	1.2	8

#	ARTICLE	IF	CITATIONS
145	Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103312.	2.0	8
146	TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. <i>Npj Precision Oncology</i> , 2021, 5, 64.	2.3	8
147	New Ways of Detecting ADRs in Neonates and Children. <i>Current Pharmaceutical Design</i> , 2015, 21, 5643-5649.	0.9	8
148	Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services. <i>Clinical Infectious Diseases</i> , 2022, 75, S11-S17.	2.9	8
149	Simple approach to dosage adjustment in patients with renal impairment. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 2505-2509.	0.5	7
150	The use of conferencing technologies to support drug policy group knowledge exchange processes: An action case approach. <i>International Journal of Medical Informatics</i> , 2011, 80, 251-261.	1.6	7
151	The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 183-192.	0.9	7
152	Genetic Markers of Cisplatin-Induced Hearing Loss in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 296-298.	2.3	7
153	Emergency department visits for children with acute asthma: discharge instructions, parental plans, and follow-through of care—a prospective study. <i>Canadian Journal of Emergency Medicine</i> , 2014, 16, 467-476.	0.5	7
154	An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26887.	0.8	7
155	Statin medications and the risk of gynecomastia. <i>Clinical Endocrinology</i> , 2018, 89, 470-473.	1.2	7
156	HUME: large-scale detection of causal genetic factors of adverse drug reactions. <i>Bioinformatics</i> , 2018, 34, 4274-4283.	1.8	7
157	Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 697-704.	0.5	7
158	Oral fluoroquinolones and risk of fibromyalgia. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 236-239.	1.1	7
159	Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicity. <i>Npj Genomic Medicine</i> , 2021, 6, 35.	1.7	7
160	An observational cohort study comparing ibuprofen and oxycodone in children with fractures. <i>PLoS ONE</i> , 2021, 16, e0257021.	1.1	7
161	An in silico framework for integrating epidemiologic and genetic evidence with health care applications: ventilation-related pneumothorax as a case illustration. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 711-720.	2.2	6
162	Big Data in the Assessment of Pediatric Medication Safety. <i>Pediatrics</i> , 2020, 145, .	1.0	6

#	ARTICLE	IF	CITATIONS
163	Guillain-Barré Syndrome Following Influenza Vaccines Affords Opportunity to Improve Vaccine Confidence. <i>Journal of Infectious Diseases</i> , 2021, 223, 355-358.	1.9	6
164	Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury. <i>Kidney360</i> , 2022, 3, 37-50.	0.9	6
165	Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2011, 18, e106-20.	1.4	6
166	Using pharmacogenetics to understand adverse drug reactions in children. <i>Paediatrics and Child Health</i> , 2011, 16, 537-538.	0.3	5
167	Improved strength on 5-hydroxytryptophan and carbidopa in spinal cord atrophy. <i>Journal of the Neurological Sciences</i> , 2017, 378, 59-62.	0.3	5
168	Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial. <i>Pregnancy Hypertension</i> , 2018, 13, 121-126.	0.6	5
169	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1233.	1.1	5
170	Regulatory approval for new pharmacogenomic tests: a comparative overview. <i>Food and Drug Law Journal</i> , 2011, 66, 1-24, i.	0.4	5
171	Asthma in British Columbia: Are we finally breathing easier? A population-based study of the burden of disease over 14 years. <i>Journal of Asthma</i> , 2017, 54, 308-317.	0.9	4
172	Physician and parent barriers to the use of oral corticosteroids for the prevention of paediatric URTI-induced acute asthma exacerbations at home. <i>Paediatrics and Child Health</i> , 2017, 22, 190-194.	0.3	4
173	Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 675-676.	0.7	4
174	Pseudotumor cerebri syndrome with different types of hormonal contraceptives in women of childbearing age. <i>European Journal of Neurology</i> , 2020, 27, 2625-2629.	1.7	4
175	DRESS induced by amoxicillin-clavulanate in two pediatric patients confirmed by lymphocyte toxicity assay. <i>Allergy, Asthma and Clinical Immunology</i> , 2021, 17, 37.	0.9	4
176	Hydroxyzine Use in Preschool Children and Its Effect on Neurodevelopment: A Population-Based Longitudinal Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 721875.	1.3	4
177	Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries. <i>Pediatric Nephrology</i> , 2023, 38, 593-604.	0.9	4
178	Diagnostic Testing for Vaccinomics: Is the Regulatory Approval Framework Adequate? A Comparison of Canada, the United States, and Europe. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 597-605.	1.0	3
179	A Literature Review on Distance Knowledge Exchange in Healthcare Groups: What Can We Learn From the ICT Literature?. <i>Journal of Medical Systems</i> , 2011, 35, 639-646.	2.2	3
180	Technology Enabled Knowledge Exchange: Development of a Conceptual Framework. <i>Journal of Medical Systems</i> , 2011, 35, 713-721.	2.2	3

#	ARTICLE	IF	CITATIONS
181	Post-renal transplant erythrocytosis: A case report. <i>Pediatric Transplantation</i> , 2015, 19, E7-10.	0.5	3
182	Risk of Pseudotumor Cerebri Syndrome (PTCS) with hormonal contraceptive use. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2018, 7, 778.	0.0	3
183	Association of Gabapentin or Pregabalin Use and Incidence of Acute Angle-closure Glaucoma. <i>Journal of Glaucoma</i> , 2019, 28, 777-779.	0.8	3
184	The incidence of symptomatic osteonecrosis after allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia – controversy on dexamethasone as a risk factor. <i>British Journal of Haematology</i> , 2019, 185, 958-959.	1.2	3
185	Novel variant in glycoprotein c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112195.	2.5	3
186	Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C. <i>Liver International</i> , 2022, 42, 796-808.	1.9	3
187	Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients. <i>Pharmacogenomics</i> , 2022, 23, 291-301.	0.6	3
188	Comment: cost of rhDNase in cystic fibrosis. <i>Annals of Pharmacotherapy</i> , 1995, 29, 1050-1051.	0.9	2
189	Camouflaged sampling and contacting of people from administrative databases: reaching target patients without knowing who they are. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 790-797.	0.9	2
190	Response to – Evaluation of Pharmacogenetic Markers to Predict the Risk of Cisplatin-Induced Ototoxicity – <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 158-158.	2.3	2
191	Risperidone Use and Risk for Gynecomastia in Men. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 656-657.	0.7	2
192	The Risk of Narcolepsy Following Receipt of Adjuvanted Pandemic 2009 The Subtype of Influenza A Virus (H1N1) Vaccines: Results of the SOMNIA Global Collaborative Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	2
193	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. <i>BMJ Open</i> , 2017, 7, e016276.	0.8	2
194	In Reply. <i>Journal of Glaucoma</i> , 2018, 27, e195-e196.	0.8	2
195	Integrating disease and drug-related phenotypes for improved identification of pharmacogenomic variants. <i>Pharmacogenomics</i> , 2021, 22, 251-261.	0.6	2
196	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 577-588.	0.7	2
197	Vaccinomics: a cross-sectional survey of public values. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2999-3015.	1.4	2
198	Deliberations about clinical pharmacogenetic testing in pediatric oncology. <i>Personalized Medicine</i> , 2021, 18, 399-405.	0.8	2

#	ARTICLE	IF	CITATIONS
199	A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112684.	2.5	2
200	Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2013, 20, e110-27.	1.4	2
201	Gene-based Warfaring Dosing. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 332.	1.0	1
202	What Is the Future of Pharmacovigilance and How Can We Make It as Good as Possible?. , 2017, , 21-30.		1
203	Risk of hair loss with different antidepressants. <i>International Clinical Psychopharmacology</i> , 2018, 33, 44-48.	0.9	1
204	Prevention of adverse drug effects: a pharmacogenomic approach. <i>Current Opinion in Pediatrics</i> , 2020, 32, 646-653.	1.0	1
205	Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 985-992.	0.9	1
206	Pharmacogenomic testing: Enhancing personalized medication use for patients. <i>Canadian Family Physician</i> , 2020, 66, 241-243.	0.1	1
207	A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110577.	0.6	1
208	Response to "Pharmacogenetics: Call to Action". <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 507-508.	2.3	0
209	Exome sequencing pilot study in children with carbamazepine-induced serious skin reactions. <i>Clinical and Translational Allergy</i> , 2014, 4, P119.	1.4	0
210	ISDN2014_0424: Challenging/disruptive sleep/wake behaviours in adolescents with fetal alcohol spectrum disorders: iatrogenic effects of prescription medications. <i>International Journal of Developmental Neuroscience</i> , 2015, 47, 128-128.	0.7	0
211	Response to The routine use of oral steroids in paediatric asthma is not routine. <i>Paediatrics and Child Health</i> , 2018, 23, 239-239.	0.3	0
212	Genome-Wide Association Studies of Drug-Induced Liver Injury Make Progress Beyond the HLA Region. <i>Gastroenterology</i> , 2019, 157, 1167-1168.	0.6	0
213	Drs. He et al. Reply to Drs. Lai and Brown. <i>Pharmacotherapy</i> , 2019, 39, 792-793.	1.2	0
214	Pharmacokinetic-Pharmacogenomic Model for Chinese Children Treated With Lamotrigine Also Applies for Mexican Children. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 801-802.	1.0	0
215	Pharmacogenomics of vincristine-induced neurotoxicity in pediatric cancer patients. <i>FASEB Journal</i> , 2013, 27, 666.3.	0.2	0
216	Analyses of Adverse Drug Reactions Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety (CPNDS) database. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR11-3.	0.0	0

#	ARTICLE	IF	CITATIONS
217	Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss. <i>Current Drug Therapy</i> , 2019, 14, 74-78.	0.2	0
218	127 Impact of CYP2D6, CYP3A4, and CYP2C9 pharmacogenomic profile on pain relief and adverse events in Canadian children treated with oxycodone and ibuprofen. <i>Paediatrics and Child Health</i> , 2021, 26, e90-e90.	0.3	0
219	Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study. <i>BMJ Paediatrics Open</i> , 2022, 6, e001428.	0.6	0
220	Pharmacogenetic testing in pediatric neurology: a pragmatic study evaluating clinician and patient perceptions. <i>Personalized Medicine</i> , 0, , .	0.8	0